Engineered CAR-T-Derived Exosomes Co-Delivering miR-145 and Cytotoxic Proteins for Targeted Solid Tumour Therapy

Quick Facts

  • Publication title: Engineered CAR-T-Derived Exosomes Co-Delivering miR-145 and Cytotoxic Proteins for Targeted Solid Tumour Therapy
  • Journal: J Extracell Vesicles
  • Year: 2026
  • DOI: 10.1002/jev2.70245
  • PMID/PMCID: 41806322; PMC12974908

Research overview

This study proposes a synergistic nanotherapeutic paradigm integrating antigen-specific killing and gene regulatory modulation, offering a promising direction for solid tumour treatment with improved safety and efficacy. Here, we develop a bioactive, cell-free therapeutic platform by engineering exosomes derived from B7-H3-targeted CAR-T cells and loading them with miR-145 (Name this exosome as exo-CT-145).

Key findings

Chimeric antigen receptor T cell (CAR-T) therapy has demonstrated remarkable efficacy in haematologic malignancies but remains constrained in solid tumours due to limited tumour penetration, immunosuppressive microenvironments and the risk of cytokine release syndrome (CRS).

Here, we develop a bioactive, cell-free therapeutic platform by engineering exosomes derived from B7-H3-targeted CAR-T cells and loading them with miR-145 (Name this exosome as exo-CT-145).

The exosomes retain CAR-specific surface markers and cytotoxic payloads (perforin and granzyme), MiR-145 is expressed at low levels in various tumours and can inhibit the occurrence and development of tumours through multiple pathways.

Exo-CT-145 significantly inhibited proliferation, migration, and Epithelial Mesenchymal Transition (EMT) of oesophageal squamous cell carcinoma (ESCC) cells and induced apoptosis in vitro.

Echo Biotech Role

Echo Biotech contributed cargo loading; the study also used or cited ExoLoad®.

Related platforms: Echosome®, Research Reagents & Tools

Related services and capabilities: Small RNA / Cargo Loading, Research Reagent / Product Supply

Related products or reagents: ExoLoad® Nucleic Acid Loading Kit

References

Original publication: Engineered CAR-T-Derived Exosomes Co-Delivering miR-145 and Cytotoxic Proteins for Targeted Solid Tumour Therapy Journal of extracellular vesicles. 2026. DOI: 10.1002/jev2.70245. PMID/PMCID: 41806322; PMC12974908.